Thermo Fisher Scientific Prices $3.8 Billion Note Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy TMO?
Source: Newsfilter
- Offering Size: Thermo Fisher Scientific has announced a $3.8 billion note offering, which includes $1 billion of 4.215% senior notes due 2031, $750 million of 4.550% senior notes due 2033, $1.3 billion of 4.902% senior notes due 2036, and $750 million of 5.546% senior notes due 2046, reflecting the company's robust capital market financing capabilities.
- Clear Use of Proceeds: The net proceeds from this offering are intended to fund a portion of the cash consideration for the pending acquisition of Clario Holdings, Inc., indicating Thermo Fisher's proactive strategy in expanding its business portfolio, while also allowing for general corporate purposes such as debt repayment and capital expenditures.
- Closing Timeline: The offering is expected to close on or about February 12, 2026, subject to customary closing conditions, providing investors with a clear timeline that enhances market confidence in the transaction.
- Strong Underwriter Lineup: The joint book-running managers for the offering include Deutsche Bank Securities, RBC Capital Markets, SMBC Nikko Securities, and Wells Fargo Securities, showcasing Thermo Fisher's strong reputation and appeal in the capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 494.540
Low
580.00
Averages
658.89
High
750.00
Current: 494.540
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Thermo Fisher to Release Q1 2026 Financial Results
- Earnings Release Schedule: Thermo Fisher will announce its Q1 2026 financial results before the market opens on April 23, 2026, expected to provide critical financial data and future outlook to help investors assess company performance.
- Conference Call Details: The company will hold a conference call at 8:30 AM ET on the same day to discuss financial performance and future expectations, with investors able to join by dialing (833) 470-1428 in the U.S. or +1 (646) 844-6383 internationally, using access code 723173.
- Live Webcast: The conference call will be webcast live on the
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
THERMO FISHER SCIENTIFIC FINALIZES PURCHASE OF CLARIO HOLDINGS, INC.
Acquisition Announcement: The Thermo Fisher Scientific has completed the acquisition of Clario Holdings, Inc.
Strategic Importance: This acquisition is expected to enhance Thermo Fisher's capabilities in the life sciences sector.
See More
High Options Volume for New York Times and Thermo Fisher Scientific
- New York Times Options: New York Times (NYT) options volume reached 22,095 contracts today, representing approximately 2.2 million shares, which constitutes 98.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Put Options: Within NYT, the $80 strike put option saw 10,001 contracts traded today, representing about 1.0 million shares, reflecting investor expectations of potential price declines, which could impact stock volatility.
- Thermo Fisher Options: Thermo Fisher Scientific Inc (TMO) options volume reached 19,487 contracts today, equating to approximately 1.9 million shares, accounting for 94% of its average daily trading volume over the past month, showcasing active market interest in its stock.
- Put Option Concerns: For TMO, the $570 strike put option traded 2,100 contracts today, representing around 210,000 shares, indicating investor concerns about potential future declines, which may affect its market performance.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.35 and a high of $160.59, with the last trade at $153.55, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to capitalize on market dynamics and opportunities.
See More
Thermo Fisher to Release Q1 2026 Financial Results
- Earnings Release Schedule: Thermo Fisher will announce its Q1 2026 financial results before the market opens on April 23, 2026, expected to provide critical financial data and future outlook to help investors assess company performance.
- Conference Call Details: The company will hold a conference call at 8:30 AM ET on the same day to discuss financial performance and future expectations, with investors able to join by dialing (833) 470-1428 in the U.S. or +1 (646) 844-6383 internationally, using access code 723173.
- Live Webcast: The conference call will be webcast live on the
See More
The Overlooked Sector of Healthcare That Has Captivated Wall Street
Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.
Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.
Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.
Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.
See More
THERMO FISHER SCIENTIFIC FINALIZES PURCHASE OF CLARIO HOLDINGS, INC.
Acquisition Announcement: The Thermo Fisher Scientific has completed the acquisition of Clario Holdings, Inc.
Strategic Importance: This acquisition is expected to enhance Thermo Fisher's capabilities in the life sciences sector.
See More
High Options Volume for New York Times and Thermo Fisher Scientific
- New York Times Options: New York Times (NYT) options volume reached 22,095 contracts today, representing approximately 2.2 million shares, which constitutes 98.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- High Volume Put Options: Within NYT, the $80 strike put option saw 10,001 contracts traded today, representing about 1.0 million shares, reflecting investor expectations of potential price declines, which could impact stock volatility.
- Thermo Fisher Options: Thermo Fisher Scientific Inc (TMO) options volume reached 19,487 contracts today, equating to approximately 1.9 million shares, accounting for 94% of its average daily trading volume over the past month, showcasing active market interest in its stock.
- Put Option Concerns: For TMO, the $570 strike put option traded 2,100 contracts today, representing around 210,000 shares, indicating investor concerns about potential future declines, which may affect its market performance.
See More
HSBC Downgrades Eli Lilly, Signals Cooling Obesity Drug Market
- Rating Downgrade: HSBC analysts downgraded Eli Lilly from Hold to Reduce, slashing the target price from $1,070 to $850, citing that the stock is currently 'priced to perfection' and faces significant competitive headwinds.
- Market Expectation Correction: Analysts argue that the total addressable market (TAM) for obesity drugs is overestimated, likely to be between $80 billion and $120 billion by 2032, rather than the consensus expectation of $150 billion, indicating that market demand may not be as robust as anticipated.
- Intensifying Competition: While Lilly's stock has risen 20% over the past year, significantly outperforming Novo Nordisk's 55% decline, analysts warn that as competitors like Novo push back in pricing, the battle for market share will intensify.
- Healthcare Sector Outlook: Despite caution on Lilly and the obesity drug market, HSBC remains bullish on the broader healthcare sector, viewing it as a safer investment amid AI disruption and geopolitical instability, and recommends focusing on AstraZeneca, AbbVie, and Johnson & Johnson for better risk-reward profiles.
See More
Analysis of XLV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XLV ETF has a 52-week low of $127.35 and a high of $160.59, with the last trade at $153.55, indicating stability and potential investment appeal in the current market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with valuable insights for technical analysis, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing significant inflows or outflows, allowing investors to capitalize on market dynamics and opportunities.
See More
